Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 08:00 ET
|
Neurona Therapeutics
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 12, 2024 16:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
March 07, 2024 16:00 ET
|
Neurona Therapeutics
Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
February 08, 2024 08:00 ET
|
Neurona Therapeutics
$120M financing will support advancement of ground-breaking regenerative cell therapies for chronic CNS disorders
Neurona Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Lifesciences Conference
February 07, 2024 16:01 ET
|
Neurona Therapeutics
Neurona Therapuetics presentation at upcoming Oppenheimer 34th Annual Healthcare Lifesciences Conference
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)
December 01, 2023 09:00 ET
|
Neurona Therapeutics
Neurona Therapeutics presents new positive clinical data from 1st cohort in Ph I/II Trial of NRTX-1001 for drug reistant focal epilepsy at AES meeting
Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy
October 19, 2023 08:00 ET
|
Neurona Therapeutics
First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
October 10, 2023 16:01 ET
|
Neurona Therapeutics
Neurona Therapeutics CEO to participate in October Investor Conferences
Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy
October 05, 2023 11:00 ET
|
Neurona Therapeutics
Publication of preclinical studies supporting ongoing open-label first-in-human Phase I/II trial of cell therapy for drug-resistant focal epilepsy
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer
July 31, 2023 08:00 ET
|
Neurona Therapeutics
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...